Scilex Holding amends merger agreement with Denali Capital Acquisition

Published 23/07/2025, 13:34
Scilex Holding amends merger agreement with Denali Capital Acquisition

Scilex Holding Company (NASDAQ:SCLX), whose stock has surged over 26% in the past week and currently trades at $8.84, announced Wednesday that its wholly owned subsidiary, Semnur Pharmaceuticals, Inc., entered into an amendment to its merger agreement with Denali Capital Acquisition Corp. and Denali Merger Sub Inc. on Tuesday.

According to a press release statement and SEC filing, Amendment No. 2 to the agreement modifies definitions related to the “Exchange Ratio” and “Merger Consideration.” The changes are intended to facilitate the issuance of additional Semnur common stock prior to the closing of the business combination. These shares may be issued in connection with potential private placement financing or to advisors and other service providers for services rendered. The amendment maintains the previously agreed 1.25-to-1 exchange ratio.

The merger agreement, as amended, outlines that Semnur will merge with Denali Merger Sub Inc., with Semnur surviving as a wholly owned subsidiary of Denali. The business combination remains subject to customary closing conditions, including shareholder approvals. According to InvestingPro data, Scilex maintains a GOOD financial health score and projects 86% revenue growth for the current fiscal year, factors that could influence the merger’s outcome.

Denali has filed a registration statement on Form S-4 with the SEC, which includes a preliminary prospectus and proxy statement related to the transaction. Denali will mail a definitive proxy statement and final prospectus to its shareholders ahead of a vote to approve the business combination.

Scilex Holding’s common stock and warrants are listed on The Nasdaq Stock Market LLC under the symbols SCLX and SCLXW, respectively.

The information in this article is based on a press release statement and details disclosed in a Form 8-K filing with the Securities and Exchange Commission.

In other recent news, Scilex Holding Company has announced new dosing guidelines for its gout medication, GLOPERBA®. This study, which has been peer-reviewed, provides critical information for the dosing of colchicine, particularly for patients with severe renal impairment—a condition affecting a significant portion of gout sufferers. The research highlights that the liquid formulation of GLOPERBA® allows for more precise dosing, potentially reducing the risk of toxicity compared to standard solid dosage forms. Additionally, Scilex has adjusted its non-employee director compensation policy following a reverse stock split. The Compensation Committee approved changes to the initial and annual stock option grants for non-employee directors, significantly reducing the number of shares granted. These adjustments align with the 1-for-35 reverse stock split of Scilex’s common stock, effective retroactively from the date of the split.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.